Top

Journal of Endocrinological Investigation

Published in:

01-09-2018 | Original Article

Presence of diabetes-specific autoimmunity in women with gestational diabetes mellitus (GDM) predicts impaired glucose regulation at follow-up

Authors: E. Cossu, M. Incani, M. G. Pani, G. Gattu, C. Serafini, A. Strazzera, L. Bertoccini, F. A. Cimini, I. Barchetta, M. G. Cavallo, M. G. Baroni

Published in: Journal of Endocrinological Investigation | Issue 9/2018

Abstract

Purpose

Gestational diabetes mellitus (GDM) is the most frequent complication of pregnancy; around 10% of GDM cases may be determined by autoimmunity, and our aims were to establish the role of autoimmunity in a population of Sardinian women affected by GDM, to find predictive factors for autoimmune GDM, and to determine type 1 diabetes (T1D) auto-antibodies (Aabs) together with glucose tolerance after a mean 21.2 months of follow-up.

Methods

We consecutively recruited 143 women affected by GDM and 60 without GDM; clinical data and pregnancy outcomes were obtained by outpatient visit or phone recall. T1D auto-antibodies GADA, IA2-A, IAA, ZnT8-A were measured in the whole population at baseline, and in the Aab-positive women at follow-up.

Results

The overall prevalence of autoimmunity was 6.4% (13/203). No significant difference was found in the prevalence of auto-antibodies between GDM (5.6%) and control (8.3%) women, neither in antibody titres. Highest titres for GADA and ZnT8-A were observed in the control group; no phenotypic factors were predictive for autoimmune GDM. Diabetes-related autoantibodies were still present in all the GDM women at follow-up, and their presence was associated with a 2.65 (p < 0.0016) relative risk (RR) of glucose impairment.

Conclusion

We observed a low prevalence (5.6%) of diabetes-related autoimmunity in our GDM cohort, consistent with the prevalence reported in previous studies. It was not possible to uncover features predictive of autoimmune GDM. However, given the significant risk of a persistent impaired glycemic regulation at follow-up, it is advisable to control for glucose tolerance in GDM women with diabetes-related autoimmunity.

Available only for authorised users

American Diabetes Association (2017) Standards of medical care in diabetes-2017: summary of revisions. Diabetes Care 40:S4–S5CrossRef

Buchanan TA, Xiang A, Kjos SL, Watanabe R (2007) What is gestational diabetes? Diabetes Care 30(Suppl 2):S105–S111CrossRefPubMed

Ferrara A, Hedderson MM, Quesenberry CP, Selby JV (2002) Prevalence of gestational diabetes mellitus detected by the national diabetes data group or the carpenter and coustan plasma glucose thresholds. Diabetes Care 25:1625–1630CrossRefPubMed

O’Sullivan EP, Avalos G, O’Reilly M, Dennedy MC, Gaffney G, Dunne F (2011) Atlantic diabetes in pregnancy (DIP): the prevalence and outcomes of gestational diabetes mellitus using new diagnostic criteria. Diabetologia 54:1670–1675CrossRefPubMed

Galtier F (2010) Definition, epidemiology, risk factors. Diabetes Metab 36:628–651CrossRefPubMed

Sacks DA, Hadden DR, Maresh M, Deerochanawong C, Dyer AR, Metzger BE et al (2012) Frequency of gestational diabetes mellitus at collaborating centers based on IADPSG consensus panel-recommended criteria: the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study. Diabetes Care 35:526–528CrossRefPubMedPubMedCentral

Lapolla A, Dalfra MG, Lencioni C, Di Cianni G (2004) Epidemiology of diabetes in pregnancy: a review of Italian data. Diabetes Nutr Metab 17:358–367PubMed

Murgia C, Berria R, Minerba L, Malloci B, Daniele C, Zedda P et al (2006) Gestational diabetes mellitus in Sardinia: results from an early, universal screening procedure. Diabetes Care 29:1713–1714CrossRefPubMed

Di Cianni G, Seghieri G, Lencioni C, Cuccuru I, Anichini R, De Bellis A et al (2007) Normal glucose tolerance and gestational diabetes mellitus: what is in between? Diabetes Care 30:1783–1788CrossRefPubMed

10.

Lapolla A, Dalfra MG, Fedele D (2009) Diabetes related autoimmunity in gestational diabetes mellitus: is it important? Nutr Metab Cardiovasc Dis 19:674–682CrossRefPubMed

11.

Nilsson C, Ursing D, Torn C, Aberg A, Landin-Olsson M (2007) Presence of GAD antibodies during gestational diabetes mellitus predicts type 1 diabetes. Diabetes Care 30:1968–1971CrossRefPubMed

12.

Yu SH, Park S, Kim HS, Park SY, Yim CH, Han KO et al (2009) The prevalence of GAD antibodies in Korean women with gestational diabetes mellitus and their clinical characteristics during and after pregnancy. Diabetes Metab Res Rev 25:329–334CrossRefPubMed

13.

Jarvela IY, Juutinen J, Koskela P, Hartikainen AL, Kulmala P, Knip M et al (2006) Gestational diabetes identifies women at risk for permanent type 1 and type 2 diabetes in fertile age: predictive role of autoantibodies. Diabetes Care 29:607–612CrossRefPubMed

14.

Cambuli VM, Incani M, Cossu E, Congiu T, Scano F, Pilia S et al (2010) Prevalence of type 1 diabetes autoantibodies (GADA, IA2, and IAA) in overweight and obese children. Diabetes Care 33:820–822CrossRefPubMed

15.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419CrossRefPubMed

16.

Cucca F, Muntoni F, Lampis R, Frau F, Argiolas L, Silvetti M et al (1993) Combinations of specific DRB1, DQA1, DQB1 haplotypes are associated with insulin-dependent diabetes mellitus in Sardinia. Hum Immunol 37:85–94CrossRefPubMed

17.

Zavattari P, Lampis R, Mulargia A, Loddo M, Angius E, Todd JA et al (2000) Confirmation of the DRB1-DQB1 loci as the major component of IDDM1 in the isolated founder population of Sardinia. Hum Mol Genet 9:2967–2972CrossRefPubMed

18.

Bruno G, Maule M, Biggeri A, Ledda A, Mannu C, Merletti F et al (2013) More than 20 years of registration of type 1 diabetes in Sardinian children: temporal variations of incidence with age, period of diagnosis, and year of birth. Diabetes 62:3542–3546CrossRefPubMedPubMedCentral

19.

Murgia C, Orru M, Portoghese E, Garau N, Zedda P, Berria R et al (2008) Autoimmunity in gestational diabetes mellitus in Sardinia: a preliminary case-control report. Reprod Biol Endocrinol 6:24CrossRefPubMedPubMedCentral

20.

Dozio N, Beretta A, Belloni C, Castiglioni M, Rosa S, Bosi E et al (1997) Low prevalence of islet autoantibodies in patients with gestational diabetes mellitus. Diabetes Care 20:81–83CrossRefPubMed

21.

Lapolla A, Fedele D, Pedini B, Dal Fra MG, Sanzari M, Masin M et al (2002) Low frequency of autoantibodies to islet cell, glutamic acid decarboxylase, and second-islet antigen in patients with gestational diabetes mellitus: a follow-up study. Ann N Y Acad Sci 958:263–266CrossRefPubMed

22.

Bo S, Menato G, Pinach S, Signorile A, Bardelli C, Lezo A et al (2003) Clinical characteristics and outcome of pregnancy in women with gestational hyperglycaemia with and without antibodies to beta-cell antigens. Diabet Med 20:64–68CrossRefPubMed

23.

Vandewalle CL, Falorni A, Svanholm S, Lernmark A, Pipeleers DG, Gorus FK (1995) High diagnostic sensitivity of glutamate decarboxylase autoantibodies in insulin-dependent diabetes mellitus with clinical onset between age 20 and 40 years. The Belgian Diabetes Registry. J Clin Endocrinol Metab 80:846–851PubMed

24.

Dereke J, Nilsson C, Landin-Olsson M, Hillman M (2012) Prevalence of zinc transporter 8 antibodies in gestational diabetes mellitus. Diabet Med 29:e436–e439CrossRefPubMed

25.

Rudland VL, Pech C, Harding AJ, Tan K, Lee K, Molyneaux L et al (2015) Zinc transporter 8 autoantibodies: what is their clinical relevance in gestational diabetes? Diabet Med 32:359–366CrossRefPubMed

26.

de Leiva A, Mauricio D, Corcoy R (2007) Diabetes-related autoantibodies and gestational diabetes. Diabetes Care 30(Suppl 2):S127–S133CrossRefPubMed

27.

Incani M, Serafini C, Satta C, Perra L, Scano F, Frongia P et al (2017) High prevalence of diabetes-specific autoimmunity in first-degree relatives of Sardinian patients with type 1 diabetes. Diabetes Metab Res Rev 33(3):e2864CrossRef

28.

Mauricio D, Corcoy R, Codina M, Morales J, Balsells M, de Leiva A (1995) Islet cell antibodies and beta-cell function in gestational diabetic women: comparison to first-degree relatives of type 1 (insulin-dependent) diabetic subjects. Diabet Med 12:1009–1014CrossRefPubMed

29.

Fallucca F, Di Mario U, Gargiulo P, Iavicoli M, Galfo C, Contreas G et al (1985) Humoral immunity in diabetic pregnancy: interrelationships with maternal/neonatal complications and maternal metabolic control. Diabete Metab 11:387–395PubMed

30.

Wucher H, Lepercq J, Carette C, Colas C, Dubois-Laforgue D, Gautier JF et al (2011) Poor prognosis of pregnancy in women with autoimmune type 1 diabetes mellitus masquerading as gestational diabetes. Diabetes Metab 37:47–51CrossRefPubMed

31.

Fuchtenbusch M, Ferber K, Standl E, Ziegler AG (1997) Prediction of type 1 diabetes postpartum in patients with gestational diabetes mellitus by combined islet cell autoantibody screening: a prospective multicenter study. Diabetes 46:1459–1467CrossRefPubMed

32.

Hod M, Merlob P, Friedman S, Schoenfeld A, Ovadia J (1991) Gestational diabetes mellitus. A survey of perinatal complications in the 1980s. Diabetes 40(Suppl 2):74–78CrossRefPubMed

33.

Whittingham S, Byron SL, Tuomilehto J, Zimmet PZ, Myers MA, Vidgren G et al (1997) Autoantibodies associated with presymptomatic insulin-dependent diabetes mellitus in women. Diabet Med 14:678–685CrossRefPubMed

34.

Piccinni MP, Lombardelli L, Logiodice F, Kullolli O, Parronchi P, Romagnani S (2016) How pregnancy can affect autoimmune diseases progression? Clin Mol Allergy 14:11CrossRefPubMedPubMedCentral

35.

Mauricio D, de Leiva A (2001) Autoimmune gestational diabetes mellitus: a distinct clinical entity? Diabetes Metab Res Rev 17(6):422–428CrossRefPubMed

36.

Hunt KJ, Logan SL, Conway DL, Korte JE (2010) Postpartum screening following GDM: how well are we doing? Curr Diab Rep 10:235–241CrossRefPubMed

Title: Presence of diabetes-specific autoimmunity in women with gestational diabetes mellitus (GDM) predicts impaired glucose regulation at follow-up
Authors: E. Cossu
M. Incani
M. G. Pani
G. Gattu
C. Serafini
A. Strazzera
L. Bertoccini
F. A. Cimini
I. Barchetta
M. G. Cavallo
M. G. Baroni
Publication date: 01-09-2018
Publisher: Springer International Publishing
Published in: Journal of Endocrinological Investigation / Issue 9/2018
Electronic ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-018-0830-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2018

Relationship between 25 hydroxyvitamin D and lipid profile in Lebanese school children

20S proteasome in the blood plasma of boys with cryptorchidism

miR15a and miR16 in Chilean type 1 diabetes patients: possible association with apoptosis, inflammatory, or autoimmunity markers

Continuously sustained elimination of iodine deficiency: a quarter of a century success in the Islamic Republic of Iran

Comparison of osteoporosis in US adults with type 1 and type 2 diabetes mellitus

Small papillary thyroid carcinoma with minimal extrathyroidal extension should be managed as ATA low-risk tumor

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials